<DOC>
	<DOCNO>NCT01282476</DOCNO>
	<brief_summary>Panobinostat drug may slow growth cancer cell kill cancer cell block certain enzyme . Panobinostat show effect cancer laboratory study . However , know show activity human . Panobinostat give participant various type cancer , include DLBCL , previous research study . In study panobinostat give antibody rituximab , FDA approve give chemotherapy DLBCL .</brief_summary>
	<brief_title>Panobinostat With Rituximab Relapsed/Refractory Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Study treatment give 4 week period call cycle . Panobinostat take orally Monday , Wednesday , Friday week . Rituximab give intravenous infusion weekly Cycle 1 per month day 1 subsequent cycle . Subjects receive 6 cycle treatment . Blood draw 2 EKGs do weekly Cycle 1 cycle . PET/CT scan do every 2 month . If disease progress 6 cycle combination panobinostat rituximab , subject may continue panobinostat alone 6 additional month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Relapsed refractory DLBCL More 1 line prior chemotherapy Currently receive anticancer therapy investigational agent Major surgery within last 4 week Known leptomeningeal brain metastasis Known HIV infection Uncontrolled fungal , bacterial , viral infection History another malignancy ( except nonmelanoma skin cancer situ cervical breast cancer ) unless disease free least 3 year Hepatitis B C positive GI disease Pregnant breastfeeding Prior treatment HDAC inhibitor include valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589</keyword>
	<keyword>LBH-589</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>DAC inhibitor</keyword>
	<keyword>deacetylase inhibitor</keyword>
	<keyword>lymphoma</keyword>
</DOC>